deltatrials
Terminated PHASE2 INTERVENTIONAL 7-arm NCT04722666

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Sponsor: Novartis Pharmaceuticals

Conditions Major Depressive Disorder With Suicidal Ideation With Intent
Interventions MIJ821 Intravenous Injection Placebo Intravenous Injection
Updated 19 times since 2021 Last updated: Apr 19, 2024 Started: Jul 20, 2021 Primary completion: Sep 26, 2023 Completion: Sep 26, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated by Novartis

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

This PHASE2 trial investigates Major Depressive Disorder With Suicidal Ideation With Intent and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 19 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2023 — May 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 14 earlier versions

  1. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  4. Feb 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  5. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  6. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  7. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  8. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  9. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  10. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  11. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  12. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  13. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Feb 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Bialystok, Poland , Birmingham, United States , Buenos Aires, Argentina , Bunkyo-ku, Japan , Bursa, Turkey (Türkiye) , DeSoto, United States , Farmington, United States , Fortaleza, Brazil and 24 more locations